Menu Search
Equities

Avicanna Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0NN:FRA

Avicanna Inc

Actions
  • Price (EUR)0.11
  • Today's Change0.007 / 6.80%
  • Shares traded2.00k
  • 1 Year change-33.73%
  • Beta0.1979
Data delayed at least 15 minutes, as of Feb 11 2026 07:39 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.

  • Revenue in CAD (TTM)25.50m
  • Net income in CAD-1.88m
  • Incorporated2016
  • Employees38.00
  • Location
    Avicanna Inc480 UNIVERSITY AVENUE, SUITE 1502TORONTO M5G 1V2CanadaCAN
  • Phone+1 (647) 243-5283
  • Fax+1 (647) 243-5283
  • Websitehttps://avicanna.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.